New CLL combo aims for Long-Term remission without lifelong pills
NCT ID NCT07624799
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests a new drug called pirtobrutinib combined with a short course of chemotherapy in 82 fit patients with untreated CLL. The goal is to achieve deep remission with undetectable cancer cells in the blood at 24 months. The treatment lasts only 15 months, aiming to control the disease long-term while reducing side effects and the risk of secondary cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pirtobrutinib (a targeted drug) plus a short course of chemotherapy (fludarabine, cyclophosphamide, obinutuzumab)
What this could lead to
If successful, this could offer a fixed-duration treatment that controls CLL deeply for years without needing lifelong medication.
What could go wrong
This is an early phase II trial with only 82 participants. Risks include side effects from chemotherapy and the drug, and the approach may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.